US FDA Feedback on Type C Meeting for ATL1102 in the US
Filed with ASX · · 2 pages · English
Percheron Therapeutics Limited on 6ix
Story so far
Earlier from Percheron Therapeutics
- Manufacture of ATL1102 clinical supplies for Phase IIb trial
- US FDA Type C Meeting for ATL1102 in DMD
- ATL1102 DMD Paediatric Investigation Plan submitted to EMA
- Half Yearly Report and Half Year Accounts
- ANP meeting with US FDA granted for ATL1102 in DMD
Later from Percheron Therapeutics
- ATL1102 for DMD EMA PIP feedback and FDA regulatory progress
- ANP and MCRI new R&D collaboration for ATL1102
- ANP Updates on US Regulatory Plans for ATL1102 in DMD
- ANP to present new proteomics data at WMS Congress 2021
- New data supports ATL1102s broader clinical potential
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics